A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction

European Heart Journal

Volumn 41, Issue 25, 2020, Pages 2356-2362

  Vaduganathan, Muthiah ^a   Jhund, Pardeep S ^b   Claggett, Brian L ^a   Packer, Milton ^c,d   Widimský, Jiri ^e   Seferovic, Petar ^f   Rizkala, Adel ^g   Lefkowitz, Martin ^g   Shi, Victor ^g   McMurray, John J V ^b   Solomon, Scott D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Placebo; Sacubitril valsartan; Statistics; Trials

Indexed keywords

PLACEBO; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; SACUBITRIL-VALSARTAN; TETRAZOLE DERIVATIVE; VALSARTAN;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; TREATMENT OUTCOME; DRUG COMBINATION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; DRUG COMBINATIONS; HEART FAILURE; HUMANS; STROKE VOLUME; TETRAZOLES; VALSARTAN; VENTRICULAR FUNCTION, LEFT;

EID: 85085756531     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehaa184     Document Type: Article

References (16)

1. Solomon SD, Vaduganathan M, L. Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, A. Pfeffer M, Desai A, H. Lund L, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen C-H, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020; 141: 352-361.
2. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016; 68: 1476-1488.
4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200.
5. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019; 381: 1609-1620.
6. Fisher LD, Gent M, Buller HR. Active-control trials: how would a new agent compare with placebo A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001; 141: 26-32.
7. Durrleman S, Chaikin P. The use of putative placebo in active control trials: two applications in a regulatory setting. Stat Med 2003; 22: 941-952.
8. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in activecontrol trials. Drug Info J 2001; 35: 435-449.
9. McMurray J, Packer M, Desai A, Gong J, Greenlaw N, Lefkowitz M, Rizkala A, Shi V, Rouleau J, Solomon S, Swedberg K, Zile MR, Andersen K, Arango JL, Arnold M, Belohlavek J, Bohm M, Boytsov S, Burgess L, Cabrera W, Chen CH, Erglis A, Fu M, Gomez E, Gonzalez A, Hagege AA, Katova T, Kiatchoosakun S, Kim KS, Bayram E, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires F, Refsgaard J, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire I, Starling RC, Vinereanu D, Teerlink JR, Wong R; PARADIGM-HF Committees and Investigators. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J 2015; 36: 434-439.
10. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776.
11. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
12. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN; SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
13. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467.
14. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14(Suppl 1): S73-S86.
15. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239.
16. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation 2020; 141: 338-351.